

**Adult CIRB - Early Phase Emphasis Meeting Agenda**

**February 3, 2026**

---

**I Continuing Review**

**10005**, A Phase 2 Study of Anti-PD-L1 Antibody (Atezolizumab) in Alveolar Soft Part Sarcoma (Version Date 03/05/25)

---

**II Continuing Review**

**10401**, A Phase 0 window-of-opportunity pharmacodynamic trial of triapine (NSC# 663249) in uterine corpus serous adenocarcinoma (Version Date 05/19/25)

---

**III Continuing Review**

**10637**, A Phase 2 Study of Venetoclax in Relapsed Classic or Variant Hairy Cell Leukemia (Version Date 10/20/25)

---

**IV Continuing Review**

**EAY191-N4**, Molecular Analysis for Combination Therapy Choice (ComboMATCH) EAY191-N4: A Randomized Trial of Selumetinib and Olaparib or Selumetinib Alone in Patients with Recurrent or Persistent RAS Pathway Mutant Ovarian and Endometrial Cancers A ComboMATCH Treatment Trial (Version Date 10/29/25)

---

**V Continuing Review**

**10464**, A Phase 1 Study of Olaparib in Combination with Durvalumab (MEDI4736) and Concurrent Radiation Therapy Following First-Line Chemotherapy in Locally Advanced Unresectable Pancreatic Cancer (Version Date 11/03/25)

---